GSK plc (GLAXF) stock
GLAXFOTCPharmaceutical PreparationsAlso trades as GSK
Financials through fiscal 2025, year ended Dec 31, 2025Score 9/30
$24.74+0.30 (+1.21%)
Close on Oct 19, 2026Market cap $106.83BP/E 13.3Yield –
GSK revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2025 it was £32.67B, up 4.1% from the year before. Over ten years it grew 3.2% a year on average. The highest annual figure on record is £33.75B in fiscal 2019.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | £32.67B | +4.1% |
| FY2024 | Dec 31, 2024 | £31.38B | +3.5% |
| FY2023 | Dec 31, 2023 | £30.33B | +3.4% |
| FY2022 | Dec 31, 2022 | £29.32B | +18.7% |
| FY2021 | Dec 31, 2021 | £24.70B | +1.4% |
| FY2020 | Dec 31, 2020 | £24.35B | -27.8% |
| FY2019 | Dec 31, 2019 | £33.75B | +9.5% |
| FY2018 | Dec 31, 2018 | £30.82B | +2.1% |
| FY2017 | Dec 31, 2017 | £30.19B | +8.2% |
| FY2016 | Dec 31, 2016 | £27.89B | +16.6% |
| FY2015 | Dec 31, 2015 | £23.92B | – |